Patenting Risk Evaluation & Mitigation Strategies; For Pharmaceuticals: A New Life Cycle Management Target for Patents?
02 January 2009
Foley Partners Stephen Maebius, Judith Waltz, David Rosen and Associate Sean Tu authored an article titled “Patenting Risk Evaluation & Mitigation Strategies; For Pharmaceuticals: A New Life Cycle Management Target for Patents?” in the January 2, 2009 issue of BNA’s Pharmaceutical Law & Industry Report.
Reproduced with permission from BNA’s Pharmaceutical Law & Industry Report, by The Bureau of National Affairs, Inc. http://www.bna.com.
Author(s)
Related Insights
23 December 2024
Labor & Employment Law Perspectives
Regulating Artificial Intelligence in Employment Decision-Making: What’s on the Horizon for 2025
Share on TwitterShare by EmailShareBack to topEmployment law in 2024 could aptly be summarized as the “Year of Artificial Intelligence Legislation.
23 December 2024
Injunction Stayed: Corporate Transparency Act Enforcement Resumes
The U.S. Department of Justice scored a victory in ongoing litigation over the constitutionality of the Corporate Transparency Act (CTA) when the Fifth Circuit Court of Appeals stayed the nationwide preliminary injunction issued earlier this month by a federal district court in Texas.
23 December 2024
Health Care Law Today
Medicare Telehealth Flexibilities Get a Three-Month Lifeline
Share on TwitterShare by EmailShareBack to topAfter much uncertainty, Congress has extended many Medicare telehealth flexibilities through March 31, 2025, in its end-of-year appropriations bill.